INFUSIONAL CISPLATIN AND ETOPOSIDE IN THE TREATMENT OF STAGE-III-B AND STAGE-IV NONSMALL CELL LUNG-CANCER - A WELL TOLERATED REGIMEN

Twenty-eight evaluable patients were treated with an infusion of cispl atin and etoposide for advanced non-small cell lung cancer. A response was demonstrated in 43%, although only two patients had documented pa rtial responses. The regimen was surprisingly low in toxicity, both ac ute and chronic, and is suitable for palliation of patients who are el derly or suffer from chronic illnesses which preclude more agressive t herapy.